Ipca's Bulk Drug 'Atenolol' registered in China

Ipca Laboratories Ltd has announced that The State Food and Drug Administration of the People's Republic of China has approved and registered the Company's Active Pharmaceutical Ingredient (API) Atenolol for importation and use in China.

It is the first such registration received by the Company from China for sale of its Active Pharmaceutical Ingredient. The Company has plans to register more APIs in China.

The Company is one of the largest producer in the world of API Atenolol and holds its Drug Master Files (DMFs) in various countries. The Company is also marketing formulations of Atenolol in various markets of CIS, Asia, Africa and Europe.

The Company is a Mumbai based fast growing fully integrated pharmaceutical Company engaged in the manufacturing and marketing of a range of pharmaceuticals world over with a strong thrust on exports. The Company's exports to over 100 countries across the globe contributed about 53% of the Company's total income of Rs 753 crores in the financial year 2005-06.

Source : Equity Bulls

Keywords